Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Quick Listen: Scrip’s Five Must-Know Things

Executive Summary

Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.

Take a brief audio tour around Scrip’s Five Must-Know Things, in this episode covering major developments in the business week ended 28 August 2020.

Making headlines this time are setbacks in multiple clinical trials, plans for hyperimmune globulin in COVID-19 and a big divestment deal in Japan.

Stories mentioned in this edition:

(Also see "Third Death In Audentes’ XLMTM Gene Therapy Trial" - Scrip, 21 Aug, 2020.)

(Also see "Novartis Hits Spartalizumab Phase III Setback In Melanoma" - Scrip, 24 Aug, 2020.)

(Also see "Bristol/Agios AML Drug Idhifa Fails In Phase III" - Scrip, 25 Aug, 2020.)

(Also see "After Blood Plasma Emergency Use Authorization, Can Takeda Develop A More Potent Alternative?" - Scrip, 24 Aug, 2020.)

(Also see "Takeda Confirms $2.3bn Deal With Blackstone For Japan Consumer Business" - Scrip, 24 Aug, 2020.)

 

Related Content

Topics

UsernamePublicRestriction

Register

LL1133951

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel